Amplia Therapeutics Ltd
ATX
Company Profile
Business description
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
Contact
350 Queen Street
Level 17
MelbourneVIC3000
AUST: +61 280033650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,741.90 | 26.70 | -0.30% |
CAC 40 | 7,804.87 | 14.60 | 0.19% |
DAX 40 | 24,304.46 | 19.12 | -0.08% |
Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
FTSE 100 | 8,837.91 | 26.87 | 0.30% |
HKSE | 23,792.54 | 114.43 | -0.48% |
NASDAQ | 19,529.95 | 231.51 | 1.20% |
Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
S&P 500 | 6,000.36 | 61.06 | 1.03% |
S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
SSE Composite Index | 3,385.36 | 1.26 | 0.04% |